Novo Nordisk’s ... acting as another of Novo Nordisk’s obesity hopefuls, the oral GLP-1 and amylin receptor amycretin, which showed 13.1% weight loss after 12 weeks in a phase 1 trial a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback